Compare MVBF & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MVBF | HUMAW |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | United States | United States |
| Employees | N/A | 220 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 333.7M | N/A |
| IPO Year | N/A | N/A |
| Metric | MVBF | HUMAW |
|---|---|---|
| Price | $27.79 | $0.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $27.60 | N/A |
| AVG Volume (30 Days) | ★ 74.4K | 14.2K |
| Earning Date | 10-29-2025 | 03-21-2025 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | ★ 73.99 | N/A |
| EPS | ★ 2.45 | N/A |
| Revenue | ★ $167,853,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.06 | N/A |
| P/E Ratio | $11.37 | ★ N/A |
| Revenue Growth | ★ 18.75 | N/A |
| 52 Week Low | $15.59 | $1.18 |
| 52 Week High | $28.72 | $1.34 |
| Indicator | MVBF | HUMAW |
|---|---|---|
| Relative Strength Index (RSI) | 62.40 | 44.95 |
| Support Level | $26.52 | $0.11 |
| Resistance Level | $28.72 | $0.15 |
| Average True Range (ATR) | 0.69 | 0.03 |
| MACD | 0.12 | 0.00 |
| Stochastic Oscillator | 72.70 | 91.78 |
MVB Financial Corp is a bank holding company. The company provides Personal banking, Business banking, and Fintech solutions. The group has identified three reportable segments: CoRe Banking, Mortgage Banking, and Financial Holding Company. The majority of ts revenue generated from the CoRe Banking segment, which includes the Fintech division, represents banking products and services offered to customers by the Bank, loans, and deposit accounts. Revenue from banking activities consists of interest earned on loans and investment securities and service charges on deposit accounts.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.